Key terms

About XOMA

XOMA Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest XOMA news

Apr 03 9:14am ET Xoma announces closing of tender offer by TipRanks Mar 11 12:01pm ET Analysts Conflicted on These Healthcare Names: Xoma (XOMA) and Lexicon Pharmaceuticals (LXRX) by TipRanks Mar 09 1:01am ET Xoma Corp. Is Worried About This – Should You Be Worried Too? by TipRanks Mar 08 4:38pm ET Xoma files $200M mixed securities shelf by TipRanks Mar 08 7:35am ET Xoma reports 2023 EPS ($4.04) vs. ($1.98) last year by TipRanks Feb 16 11:25am ET Strategic Acquisitions and Royalty Income Streams Justify Buy Rating for Xoma by TipRanks Feb 16 11:25am ET Xoma acquisition boosts royalty growth potential, says H.C. Wainwright by TipRanks Feb 16 9:22am ET Xoma Corp Secures Merger with Kinnate Biopharma Inc. by TipRanks Feb 16 8:05am ET Xoma to acquire Kinnate for between $2.3352-$2.5879 per share plus CVR by TipRanks Feb 16 8:03am ET Xoma to acquire Kinnate Biopharma for between $2.3352-$2.5879 per share plus CVR by TipRanks Jan 22 1:17pm ET Buy Rating Affirmed for Xoma: Strategic Royalty Acquisitions and Financial Agility Underpin Investment Potential by TipRanks Jan 18 8:35am ET Xoma expands commercial royalty, milestone portfolio with DSUVIA acquisition by TipRanks Jan 11 4:12pm ET Xoma to make $1M payment to LadRx after FDA acceptance of arimoclomol NDA by TipRanks Jan 08 7:53am ET Xoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairman by TipRanks

No recent press releases are available for XOMA

XOMA Financials

1-year income & revenue

Key terms

XOMA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

XOMA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming